Likelihood of Approval and Phase Transition Success Rate Model – Entinostat in Solid Tumor
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Entinostat in Solid Tumor report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Entinostat in Solid Tumor Drug Details:
Entinostat (Jingzhuda) is an antineoplastic agent. It is formulated as tablets for oral route of administration. Jingzhuda is indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative breast cancer who have relapsed or progressed after endocrine therapy and for advanced or metastatic breast cancer.Entinostat is under development for the treatment of metastatic HER2- breast cancer, solid tumors, T-cell lymphomas and unspecified B-cell lymphomas. The drug candidate is a new molecular entity which is administered through oral route. It targets histone deacetylase 1. The drug candidate was under development for the treatment of relapsed or refractory acute lymphocytic leukemia, metastatic breast cancer and refractory acute myelocytic leukemia, triple negative breast cancer, small cell lung cancer and metastatic brain tumor, metastatic uveal melanoma, metastatic colorectal cancer, fallopian tube cancer, peritoneal cancer, epithelial ovarian cancer, metastatic renal cell carcinoma, metastatic melanoma, follicular lymphoma, myelodysplastic syndrome, chronic myelocytic leukemia, acute myelocytic leukemia, pancreatic ductal adenocarcinoma, cholangiocarcinoma, non-small cell lung cancer, adenoid cystic carcinoma, muscle invasive bladder cancer, refractory or relapsed Hodgkin lymphoma, endometrioid endometrial adenocarcinoma, muscle invasive bladder cancer, recurrent or refractory CNS tumors and lymphoma.It was also under development for human papillomavirus (HPV) associated cancers, including metastatic solid tumors, lung cancer and esophagus cancer, colon cancer, cervical cancer, peripheral T-cell lymphoma (PTCL), oropharyngeal cancer, anal cancer, colorectal cancer, vulvar cancer, vaginal cancer and penile cancer.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Entinostat LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports